QCG
DPLO

Quadrant Capital Group’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History

Quadrant Capital Group’s Portfolio DPLO Stock Details DPLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-170
Closed – – 2363
2019
Q4 		$0 Buy
+170
New +$798 ﹤0.01% 2547
2019
Q2 		– Sell
-61
Closed – – 2456
2019
Q1 		$0 Hold
61
– – ﹤0.01% 2380
2018
Q4 		$0 Sell
61
-418
-87% -$7.05K ﹤0.01% 2366
2018
Q3 		$8K Sell
479
-37
-7% -$788 ﹤0.01% 1407
2018
Q2 		$12K Sell
516
-74
-13% -$1.73K ﹤0.01% 1201
2018
Q1 		$8K Buy
590
+172
+41% +$4.01K ﹤0.01% 1386
2017
Q4 		$8K Sell
418
-145
-26% -$2.85K ﹤0.01% 1307
2017
Q3 		$11K Hold
563
– – ﹤0.01% 1157
2017
Q2 		$8K Buy
563
+418
+288% +$6.97K ﹤0.01% 1197
2017
Q1 		$2K Hold
145
– – ﹤0.01% 1703
2016
Q4 		$1K Hold
145
– – ﹤0.01% 1888
2016
Q3 		$4K Buy
145
+50
+53% +$1.68K ﹤0.01% 1340
2016
Q2 		$3K Sell
95
-8
-8% -$251 ﹤0.01% 1386
2016
Q1 		$2K Sell
103
-185
-64% -$5.45K ﹤0.01% 1393
2015
Q4 		$9K Buy
+288
New +$8.98K 0.01% 851

Other funds holding DPLO

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Quadrant Capital Group's DPLO Position: Q1 2020 in Review

Quadrant Capital Group sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q1 2020, closing a stake of 170 shares.

Quadrant Capital Group first reported a position in DPLO in Q4 2015 and held it in 15 quarters. The position peaked at $12K in Q2 2018. 1 fund tracked by Wall St. Rank holds DPLO as of Q1 2020.

  • Quadrant Capital Group reported no remaining DIPLOMAT PHARMACY, INC. position as of Q1 2020 after selling out during the quarter.
  • Quadrant Capital Group sold 170 DIPLOMAT PHARMACY, INC. shares in Q1 2020.
  • Quadrant Capital Group first reported a position in DIPLOMAT PHARMACY, INC. in Q4 2015 and held it in 15 quarters.
  • Quadrant Capital Group's DIPLOMAT PHARMACY, INC. position peaked at $12K in Q2 2018.
  • 1 fund tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q1 2020.

Based on Quadrant Capital Group's 13F filing for Q1 2020, filed 15 May 2020.